Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558651 | 1.00 | PTGS2 (0.43) | PTGS2SRCALDH1A1L3MBTL1POLB | |
| SCHEMBL5547116 | 1.00 | PTGS2 (0.43) | PTGS2SRCALDH1A1L3MBTL1POLB | |
| SCHEMBL6422823 | 0.91 | PTGS2 (0.37) | PTGS2SRCALDH1A1L3MBTL1POLB | |
| SCHEMBL5560512 | 0.91 | ALDH1A1 (0.37) | PTGS2SRCALDH1A1L3MBTL1POLB | |
| SCHEMBL5560516 | 0.91 | ALDH1A1 (0.37) | PTGS2SRCALDH1A1L3MBTL1POLB | |
| SCHEMBL5554442 | 0.89 | SRC (0.40) | PTGS2SRCALDH1A1KMT2AAKR1C3 | |
| SCHEMBL5550631 | 0.89 | SRC (0.40) | PTGS2SRCALDH1A1KMT2AAKR1C3 | |
| SCHEMBL5554437 | 0.89 | SRC (0.40) | PTGS2SRCALDH1A1KMT2AAKR1C3 | |
| SCHEMBL2003460 | 0.89 | SRC (0.50) | PTGS2SRC | |
| SCHEMBL5561760 | 0.89 | POLB (0.38) | PTGS2SRCALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643961-A4 | COX-2 AND FAAH INHIBITORS | MICROBIA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006050120-A2 | SYNTHESIS OF COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1643961-A2 | COX-2 AND FAAH INHIBITORS | Microbia, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005002525-A2 | COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | PTGS2 3/4885SRC 3883/4885ALDH1A1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.